N/A N=24 Wiring Adolescents With Social Anxiety Via Behavioral Interventions
Social Anxiety
Primary: Ecological Momentary Assessment (EMA) Adherence — 53 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=41 Electroconvulsive Therapy Amplitude Titration
Major Depressive Disorder
Primary: Beta Coefficient From Linear Regression of Amplitude-determined Seizure (Independent Variable) and Ebrain (Dependent Variable) — -.0001054 beta coefficient from linear…
Phase 2 N=32 Mifepristone for the Prevention of Relapses of Alcohol Drinking
Alcohol Use Disorders (AUD)
Primary: Number of Participants Experiencing Adverse Events in the Mifepristone Versus Placebo Group as a Measure of Safety and Tolerability — 0; 3 Participants — p=>.05
N/A N=24 Capsule Endoscopy for HEmorrhage in the ER
Upper Gastrointestinal Bleeding
Primary: Number of Participants Discharged for Outpatient Management of Upper GI Bleeds — 3; 9 Participants
Phase 2 N=12 Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma
Glioma · High Grade Astrocytoma · Glioblastoma Multiforme
Primary: Number of Participants Experiencing the Incidence of Grade One or Higher Adverse Events — 12 participants
N/A N=29 Prenatal Mindfulness & Hypertension Study
Hypertension in Pregnancy
Primary: Retention and Adherence — 12; 11 Participants
N/A N=46 Targeting Body Image Among Women of Higher Body Weight
Obesity · Overweight · Body Image
Primary: EDE-Q Weight and Shape Concern — 3; 6; 0; 3 Participants
N/A N=332 COVID-19 MP Biomedicals SARS-CoV-2 Ag OTC: Clinical Evaluation
SARS-CoV2 Infection · COVID-19
Primary: Positive Percent Agreement — 53; 2 Participants
Phase 3 N=526 Study of Cingal for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow up
Knee Osteoarthritis
Primary: OMERACT-OARSI Responder Rate at 39 Weeks — 91.2; 92.4; 93.2 Percentage of subjects — p=0.8106
Phase 4 N=107 Decreasing Intraoperative Skin Damage in Prone Position Surgeries
Pressure Injury
Primary: Number of Participants With Intraoperative Acquired Pressure Injuries (IAPI) — 13; 14 Participants
Phase 2 N=56 Therapeutic Vaccination in Treated HIV Disease
HIV-1-infection
Primary: The Percentage of Participants With Grade 3 or Higher Treatment-related Adverse Events — 0; 0; 0; 0 Participants
N/A N=252 Personalized Feedback Programs for College Students
Alcohol Use, Unspecified
Primary: Change in Alcohol Use — 19; 17; 22; 18 Participants
Phase 3 N=231 Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis
Scalp Psoriasis
Primary: The Proportion of Subjects With Investigator Global Assessment Mod 2011 (Scalp) Score of "Clear" and "Almost Clear" With at Least 2-point Reduction From Baseline at Week…
Phase 2 N=213 P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris
Acne Vulgaris
Primary: Absolute Change in Inflammatory Lesion Counts — -7.7; -4.1; -11.2; -11.3 inflammatory acne lesions
Phase 2 N=6 Exemestane in Post-Menopausal Women With NSCLC
Non-Small Cell Lung Cancer
Primary: Disease Response (RECIST) — NA days